The Squamous Non-Small Cell Lung Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Squamous Non-Small Cell Lung Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Squamous Non-Small Cell Lung Cancer and features dormant and discontinued products.
GlobalData tracks 151 drugs in development for Squamous Non-Small Cell Lung Cancer by 106 companies/universities/institutes. The top development phase for Squamous Non-Small Cell Lung Cancer is phase ii with 84 drugs in that stage. The Squamous Non-Small Cell Lung Cancer pipeline has 147 drugs in development by companies and four by universities/ institutes. Some of the companies in the Squamous Non-Small Cell Lung Cancer pipeline products market are: BeiGene, F. Hoffmann-La Roche and AstraZeneca.
The key targets in the Squamous Non-Small Cell Lung Cancer pipeline products market include Programmed Cell Death Protein 1, DNA Topoisomerase I, and Epidermal Growth Factor Receptor ERB1.
The key mechanisms of action in the Squamous Non-Small Cell Lung Cancer pipeline product include Programmed Cell Death Protein 1 Antagonist with 24 drugs in Phase III. The Squamous Non-Small Cell Lung Cancer pipeline products include 12 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Squamous Non-Small Cell Lung Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Squamous Non-Small Cell Lung Cancer overview
Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer’s extent. Treatment options depend on the stage but may include surgery, chemotherapy, radiation therapy, or targeted therapies. Prognosis varies based on factors like stage and overall health. Research continues to explore new therapies and personalized approaches for improved outcomes in squamous NSCLC patients.
For a complete picture of Squamous Non-Small Cell Lung Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
